Edward Green
Founder
CB
CHAIN Biotechnology
CHAIN Biotechnology develops oral vaccines and immunotherapies using its Clostridium Assisted Drug Delivery (CADD™) platform, which precisely targets the lower gastrointestinal tract. The company focuses on chronic gut-related diseases by delivering specific therapeutic payloads to improve patient outcomes in this area.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$2.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many chronic gut-related diseases require targeted drug delivery to the lower gastrointestinal (GI) tract, which is difficult to achieve with traditional oral medications that are often degraded or absorbed before reaching the intended site. This lack of precision can lead to reduced efficacy and increased systemic side effects.
Solution
CHAIN Biotechnology develops oral vaccines and immunotherapies that precisely target the lower GI tract using its Clostridium Assisted Drug Delivery (CADD™) platform. The CADD™ platform utilizes a specific Clostridium bacterial strain, engineered to produce and deliver therapeutic payloads directly to the lower GI tract. This targeted approach aims to improve patient outcomes by ensuring that the therapeutic agent reaches the intended site of action, maximizing efficacy while minimizing off-target effects. The company has several therapeutic candidates in pre-clinical development.
Target Audience
The primary target audience includes individuals suffering from chronic gut-related diseases, as well as pharmaceutical companies seeking innovative drug delivery solutions for gastrointestinal disorders.
Features
- Clostridium Assisted Drug Delivery (CADD™) platform for targeted delivery to the lower GI tract
- Precision engineering biology to produce and deliver specific therapeutic payloads
- Oral administration for improved patient compliance
- Focus on chronic gut-related diseases
- Therapeutic candidates in pre-clinical development